BRPI0809034A2 - Composição útil para a prevenção de diabetes tipo 2 e suas complicações em pacientes pré-diabéticos com resistência à insulina - Google Patents

Composição útil para a prevenção de diabetes tipo 2 e suas complicações em pacientes pré-diabéticos com resistência à insulina

Info

Publication number
BRPI0809034A2
BRPI0809034A2 BRPI0809034-3A2A BRPI0809034A BRPI0809034A2 BR PI0809034 A2 BRPI0809034 A2 BR PI0809034A2 BR PI0809034 A BRPI0809034 A BR PI0809034A BR PI0809034 A2 BRPI0809034 A2 BR PI0809034A2
Authority
BR
Brazil
Prior art keywords
complications
diabetes
prevention
type
insulin resistant
Prior art date
Application number
BRPI0809034-3A2A
Other languages
English (en)
Inventor
Claudio Cavazza
Paolo Carminati
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of BRPI0809034A2 publication Critical patent/BRPI0809034A2/pt
Publication of BRPI0809034A8 publication Critical patent/BRPI0809034A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BRPI0809034A 2007-03-21 2008-03-21 Composição útil para a prevenção de diabetes tipo 2 e suas complicações em pacientes pré-diabéticos com resistência à insulina BRPI0809034A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07104624 2007-03-21
PCT/EP2008/053437 WO2008113862A2 (en) 2007-03-21 2008-03-21 Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance

Publications (2)

Publication Number Publication Date
BRPI0809034A2 true BRPI0809034A2 (pt) 2014-10-07
BRPI0809034A8 BRPI0809034A8 (pt) 2017-12-26

Family

ID=38328657

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809034A BRPI0809034A8 (pt) 2007-03-21 2008-03-21 Composição útil para a prevenção de diabetes tipo 2 e suas complicações em pacientes pré-diabéticos com resistência à insulina

Country Status (25)

Country Link
US (1) US8389574B2 (pt)
EP (1) EP2136798B1 (pt)
JP (2) JP5982091B2 (pt)
KR (1) KR20090120503A (pt)
CN (1) CN101663030B (pt)
AU (1) AU2008228192B2 (pt)
BR (1) BRPI0809034A8 (pt)
CA (1) CA2681185C (pt)
CY (1) CY1116872T1 (pt)
DK (1) DK2136798T3 (pt)
EA (1) EA018442B1 (pt)
ES (1) ES2546619T3 (pt)
HK (1) HK1139040A1 (pt)
HR (1) HRP20150936T1 (pt)
HU (1) HUE025394T2 (pt)
IL (1) IL201014A (pt)
MX (1) MX2009009966A (pt)
MY (1) MY151623A (pt)
NZ (1) NZ579767A (pt)
PL (1) PL2136798T3 (pt)
PT (1) PT2136798E (pt)
SG (2) SG193655A1 (pt)
SI (1) SI2136798T1 (pt)
WO (1) WO2008113862A2 (pt)
ZA (1) ZA200907280B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8589106B2 (en) * 2010-12-22 2013-11-19 Roche Diagnostics Operations, Inc. Calibration of a handheld diabetes managing device that receives data from a continuous glucose monitor
KR20190043076A (ko) * 2017-10-17 2019-04-25 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 당뇨병을 동반한 심혈관계 질환의 예방 또는 치료용 약학 조성물 및 이를 포함하는 복합제제
CN115068451A (zh) * 2021-03-15 2022-09-20 中国医学科学院药物研究所 竹红菌素类化合物作为ltb4受体抑制剂的医药用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670827C3 (de) * 1967-03-20 1974-10-24 Bayer Ag, 5090 Leverkusen 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin
IT1254314B (it) * 1992-03-27 1995-09-14 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
US5925656A (en) * 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
IT1290801B1 (it) * 1996-07-05 1998-12-11 Mendes Srl Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
IT1293067B1 (it) * 1997-07-01 1999-02-11 Sigma Tau Ind Farmaceuti Composizione farmaceutica per il trattamento di patologie causate da alterato metabolismo lipidico
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US6281234B1 (en) * 1998-05-12 2001-08-28 American Home Products Corporation (2-Acylaminothiazole-4-yl)acetic acid derivative
IT1302289B1 (it) * 1998-09-30 2000-09-05 Univ Catania Composizioni farmaceutiche ad attivita' antineoplastica
CA2375378C (en) * 1999-06-08 2009-08-11 Arduino Arduini Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines
ITRM20010294A1 (it) * 2001-05-29 2002-11-29 Sigma Tau Ind Farmaceuti Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re
US20030068391A1 (en) * 2001-10-04 2003-04-10 Harris Dennis H. Ingestible nerve and circulatory nutritional formulation

Also Published As

Publication number Publication date
IL201014A0 (en) 2010-05-17
ES2546619T3 (es) 2015-09-25
CN101663030B (zh) 2013-08-21
BRPI0809034A8 (pt) 2017-12-26
CA2681185C (en) 2018-05-01
NZ579767A (en) 2012-04-27
JP5982091B2 (ja) 2016-08-31
CN101663030A (zh) 2010-03-03
JP5974056B2 (ja) 2016-08-23
AU2008228192B2 (en) 2013-02-07
EA018442B1 (ru) 2013-08-30
DK2136798T3 (en) 2015-08-31
WO2008113862A2 (en) 2008-09-25
SI2136798T1 (sl) 2015-10-30
PT2136798E (pt) 2015-10-15
US20100048691A1 (en) 2010-02-25
HRP20150936T1 (hr) 2015-09-25
EP2136798B1 (en) 2015-07-29
AU2008228192A1 (en) 2008-09-25
JP2010521536A (ja) 2010-06-24
EA200970877A1 (ru) 2010-04-30
MX2009009966A (es) 2009-10-07
ZA200907280B (en) 2010-06-30
HUE025394T2 (en) 2016-02-29
IL201014A (en) 2017-06-29
SG10201507488RA (en) 2015-10-29
JP2014237717A (ja) 2014-12-18
CA2681185A1 (en) 2008-09-25
WO2008113862A3 (en) 2008-12-31
US8389574B2 (en) 2013-03-05
HK1139040A1 (en) 2010-09-10
CY1116872T1 (el) 2017-04-05
SG193655A1 (en) 2013-10-30
KR20090120503A (ko) 2009-11-24
MY151623A (en) 2014-06-30
EP2136798A2 (en) 2009-12-30
PL2136798T3 (pl) 2015-11-30

Similar Documents

Publication Publication Date Title
IL275890A (en) A pharmaceutical preparation containing rasgelin and pramipexole
EP2070540A4 (en) DRUG COMPOSITION FOR THE TREATMENT OF DIABETES TYPE 2 AND CHRONIC NEOPATHY
BRPI0923167A2 (pt) "mecanismo de intertravamento para um dispositivo de didtribuição fármaco e dispositivo de distribuição de fármaco"
ATE502960T1 (de) Lingo bindende moleküle und pharmazeutische verwendung davon
EP2161021A4 (en) MEDICAL FILM PREPARATION WITH FAST RESOLUTION AND FLEXIBILITY
IL195947A (en) Manicured cyclic compounds and pharmaceutical preparations containing them for use @ for prevention @ and treatment @ for diabetes
IL200278A (en) Use of aclidinium for the manufacture of a drug for use in the treatment or prevention of respiratory illness and pharmacist's preparation for the treatment or prevention of respiratory illness
IL216928A (en) A crystalline form of 2- {4- [n- (5,6-diphenylpyrazine-2-ram) - n-isopropylamino] butoxy} - n- (methylsulfonyl) acetamide, its pharmaceutical composition and its use in the preparation of a drug
EP2081957A4 (en) EXENDIN OR ANALOGUE OF EXENDIN MODIFIED BY PEG, COMPOSITIONS THEREOF AND USE THEREOF
HK1140154A1 (en) Improvements in and relating to drive mechanisms suitable for use in drug delivery devices
BRPI0809260A2 (pt) Dispositivo para a assistência médica de um paciente em uma emergência
CL2007003440A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida
EP2162003A4 (en) THERAPEUTIC TREATMENT OF METABOLIC SYNDROME, TYPE 2 DIABETES, OBESITY OR PRE-DIABETES
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
PL2340809T3 (pl) Lek zawierający fluorochinoliny
BRPI0821264A2 (pt) Mistura e produto refratário que tem uma alta resistência à hidratação produzida partindo da mesma
BRPI0716754A2 (pt) composiÇço À base de xantoxilina e a respectiva utilizaÇço em cosmÉtica
BRPI0809034A2 (pt) Composição útil para a prevenção de diabetes tipo 2 e suas complicações em pacientes pré-diabéticos com resistência à insulina
BRPI0814100A2 (pt) Composição e método para minimizar a descoloração em uma composição de cuidado oral
EP2117519A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF TRAMADOL AND KETOPROFEN
IL202305B (en) Use of a preparation containing a cellular filament taci region or a part of it that binds blys and a constant region of immunoglobulin of human origin for the preparation of a drug for the treatment of sle in a patient suffering from mild to moderate sle
EP1792620A4 (en) MEDICAL COMPOSITION WITH AN AGENT AGAINST DIABETES
BRPI0821539A2 (pt) composição para a prevenção e o tratamento de doenças metabólicas compreendendo o extrato de lysimachiae foenum-graeci herma
HK1130177A1 (en) A pharmaceutical composition for treating type ii diabetes and complications thereof
BRPI0906045A2 (pt) "composição farmacêutica para administração nasal"

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: ALFASIGMA S.P.A. (IT)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL